What Is Myocardial Depressant Factor? Definition and What Research Reports

Myocardial depressant factor (MDF) is a descriptive, umbrella term used in cardiovascular and critical-care research for any circulating substance that lowers the contractile performance of heart muscle during states such as sepsis, endotoxaemia, cardiogenic shock or haemorrhage. The phrase describes a function rather than a single chemical entity: a sample of plasma or serum is said to contain “myocardial depressant activity” when it reduces the shortening or force generation of isolated cardiac cells or tissue, and the molecule or molecules responsible for that activity are then called myocardial depressant factors. Over several decades of work, different laboratories have nominated different candidates, so the term is best read as a research category that groups together peptides, proteins, enzymes and cytokines linked to reversible cardiac depression. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about heart function, sepsis or medical treatment.

What Class of Molecule Is It?

There is no single molecular class that defines MDF. The candidates that appear in the peer-reviewed literature are mostly water-soluble peptides and proteins found in blood, and they fall into a few broad groups:

• Peptide fragments of larger secretory proteins — for example vasostatin-I, a fragment derived from chromogranin A, which a 2020 report in the British Journal of Clinical Pharmacology described as an adrenal gland-released myocardial depressant factor (PMID 31726481).
• Circulating enzymes — dipeptidyl peptidase 3 (DPP3), a cytosolic peptidase that can appear in the circulation, was characterised as a myocardial depressant factor in a 2020 European Journal of Heart Failure study (PMID 31472040).
• Cytokines — interleukin 6 (IL-6) and macrophage migration inhibitory factor (MIF) have both been investigated as mediators of cardiac depression in septic and endotoxin models (PMID 14738793; PMID 12946935).
• Unfractionated plasma activity — in some papers the “factor” is still an incompletely identified activity present in patient serum, as in a 2002 Critical Care Medicine characterisation of a myocardial depressant factor in meningococcal septicaemia (PMID 12394943).

Where the Proposed Factors Come From

The proposed sources differ by candidate and by model. Researchers reported vasostatin-I as being released from the adrenal gland, framing it as an endocrine contributor to cardiac depression (PMID 31726481). In contrast, a 2003 study in American Journal of Physiology – Heart and Circulatory Physiology described macrophage migration inhibitory factor as a cardiac-derived myocardial depressant factor, meaning the heart itself was identified as a source of the mediator acting on it (PMID 12946935). Dipeptidyl peptidase 3 is normally an intracellular enzyme, and the study that characterised circulating DPP3 examined it as a blood-borne depressant signal and tested what happened when it was inhibited (PMID 31472040). Cytokine candidates such as IL-6 are produced largely by immune cells during systemic inflammation, and the meningococcal sepsis literature examined IL-6 in plasma from affected children (PMID 14738793).

How the Term Is Used in Peptide Research

In peptide-focused literature the term appears in three recurring ways. First, as a classification label: a newly characterised peptide or protein is called “a myocardial depressant factor” when experiments show it reduces cardiac contractility, which is exactly how the vasostatin-I and DPP3 papers framed their findings (PMID 31726481; PMID 31472040). Second, as a bioassay concept: plasma or serum is applied to cardiomyocytes or isolated heart preparations, and any fall in contractility is attributed to depressant factors in that fluid, an approach used in the meningococcal septicaemia work (PMID 12394943). Third, as a target concept: investigators neutralise or inhibit a suspected factor and observe whether cardiac function changes, as in an endotoxin model where researchers tested macrophage migration inhibitory factor neutralisation (PMID 15879312).

Importantly, in this literature the peptides and proteins involved are studied as endogenous mediators of disease, not as administered research peptides with a performance or therapeutic framing. Where a molecule is given experimentally, it is usually to reproduce the depressant effect in a controlled setting, or an antibody or inhibitor is given to remove the effect.

What the Published Literature Reports

Sepsis and meningococcal shock

A 2002 Critical Care Medicine study set out to characterise a myocardial depressant factor present in meningococcal septicaemia, treating the depressant activity of patient serum as the object of study (PMID 12394943). A 2004 Lancet report then examined interleukin 6 as a contributor to the myocardial dysfunction of meningococcal septic shock (PMID 14738793). Follow-up work published in 2011 reported that the myocardial depressant effects of interleukin 6 in meningococcal sepsis were regulated by p38 mitogen-activated protein kinase, implicating an intracellular signalling route rather than the cytokine alone (PMID 21494108).

Endotoxin models

In experimental endotoxaemia, researchers described macrophage migration inhibitory factor as a cardiac-derived myocardial depressant factor (PMID 12946935), and a 2005 Circulation Research study examined endotoxin-induced myocardial dysfunction and the effects of neutralising that factor (PMID 15879312). A 2003 PNAS paper took a broader approach, identifying and characterising endotoxin-induced myocarditis and profiling gene expression changes in the affected heart (PMID 14623955).

Haemorrhagic shock

Depressant signalling has also been studied outside infection. A 2005 report in American Journal of Physiology – Regulatory, Integrative and Comparative Physiology examined signalling for myocardial depression in haemorrhagic shock and the roles of Toll-like receptor 4 and the p55 tumour necrosis factor-alpha receptor (PMID 15514106).

Newer circulating candidates

The 2020 European Journal of Heart Failure study reported that circulating dipeptidyl peptidase 3 acted as a myocardial depressant factor and that inhibiting DPP3 rapidly and sustainably improved haemodynamics in its experimental setting (PMID 31472040). In the same period, researchers reported adrenal gland-released vasostatin-I as a myocardial depressant factor (PMID 31726481).

Candidate factors at a glance

Effects Described Across Models: What Studies Report

Across these papers, the common thread is reversible loss of contractile performance linked to a circulating mediator rather than to permanent structural damage, with the 2003 PNAS work describing endotoxin-induced myocarditis and its gene expression signature in detail (PMID 14623955). Several studies reported that interfering with a specific mediator changed the outcome: neutralisation of macrophage migration inhibitory factor was examined in endotoxin-induced myocardial dysfunction (PMID 15879312), inhibition of dipeptidyl peptidase 3 was reported to improve haemodynamics (PMID 31472040), and blocking p38 mitogen-activated protein kinase was linked to the interleukin 6 depressant effect in meningococcal sepsis (PMID 21494108). These are experimental and clinical-research observations in the cited settings; they are not statements about clinical practice.

Limits of the Evidence

• No single agreed molecule. Different laboratories have nominated different factors, and the cited papers each describe their own candidate rather than a unified definition.
• Model dependence. Findings come from meningococcal sepsis cohorts, endotoxin models and haemorrhagic shock models, and results in one setting do not automatically transfer to another.
• Assay dependence. “Depressant activity” is defined by the contractility assay used, so comparisons across studies are not straightforward.
• Not a consumer or performance concept. The molecules discussed here are endogenous mediators studied in critical illness, and none of the cited work supports any personal use framing.

Related Terms

• Septic cardiomyopathy — the reversible cardiac dysfunction seen in sepsis, which MDF research attempts to explain mechanistically.
• Cytokine-mediated cardiac depression — the subset of MDF research focused on interleukin 6 and macrophage migration inhibitory factor (PMID 14738793).
• Endotoxin-induced myocarditis — the lipopolysaccharide model used to study these mediators (PMID 14623955).

Again, this entry is definitional and educational only; it is not medical advice, and clinical questions belong with a licensed physician.

References

• Adrenal gland-released vasostatin-I is a myocardial depressant factor (British Journal of Clinical Pharmacology, 2020)
• Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics (European Journal of Heart Failure, 2020)
• Characterization of a myocardial depressant factor in meningococcal septicemia (Critical Care Medicine, 2002)
• Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization (Circulation Research, 2005)
• Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock (Lancet, 2004)
• Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase (Critical Care Medicine, 2011)
• Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis (PNAS, 2003)
• Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor (American Journal of Physiology – Heart and Circulatory Physiology, 2003)
• Signaling for myocardial depression in hemorrhagic shock: roles of Toll-like receptor 4 and p55 TNF-alpha receptor (American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, 2005)